ACAD
35.91
-0.72
-1.97%
AEMD
7.6
+0.01
+0.13%
APRI
1.78
+0.08
+4.71%
ARNA
2.56
-0.15
-5.54%
ATEC
0.58
0.00
+0.87%
CNAT
3.73
-0.2
-5.09%
CRXM
0.35
-0.02
-5.41%
CYTX
0.38
+0.02
+4.94%
DXCM
87.82
-6.32
-6.71%
GNMK
9.66
-0.68
-6.58%
HALO
16.62
-0.84
-4.81%
ILMN
193.13
-4.48
-2.27%
INNV
0.13
-0.018
-12.2297%
INO
7.1
-0.39
-5.21%
ISCO
3.8
-0.1
-2.56%
ISIS
48.75
-1.43
-2.85%
LGND
88.48
-3.46
-3.76%
LPTN
0.25
+0.02
+8.70%
MBVX
1.8
+0.05
+2.86%
MEIP
1.8
-0.02
-1.10%
MNOV
3.05
+0.1
+3.39%
MRTX
26.57
+0.75
+2.90%
MSTX
0.48
-0.01
-1.03%
NBIX
47.05
+0.67
+1.44%
NUVA
52.01
-0.71
-1.35%
ONCS
5.77
+0.39
+7.25%
ONVO
2.45
-0.28
-10.26%
OREX
2.68
-0.09
-3.25%
OTIC
21.45
-1.22
-5.38%
QDEL
20.28
-0.31
-1.51%
RCPT
231.96
0.00
0.00%
RGLS
8.26
-0.07
-0.84%
RMD
50.75
-1.19
-2.29%
SCIE
0.014
0.00
0.00%
SPHS
0.85
-0.05
-5.56%
SRNE
12.46
-0.22
-1.74%
TROV
5.72
-0.23
-3.87%
VICL
0.61
+0.02
+3.35%
VOLC
18
0.00
0.00%
ZGNX
18.48
-0.74
-3.85%
ACAD
35.91
-0.72
-1.97%
AEMD
7.6
+0.01
+0.13%
APRI
1.78
+0.08
+4.71%
ARNA
2.56
-0.15
-5.54%
ATEC
0.58
0.00
+0.87%
CNAT
3.73
-0.2
-5.09%
CRXM
0.35
-0.02
-5.41%
CYTX
0.38
+0.02
+4.94%
DXCM
87.82
-6.32
-6.71%
GNMK
9.66
-0.68
-6.58%
HALO
16.62
-0.84
-4.81%
ILMN
193.13
-4.48
-2.27%
INNV
0.13
-0.018
-12.2297%
INO
7.1
-0.39
-5.21%
ISCO
3.8
-0.1
-2.56%
ISIS
48.75
-1.43
-2.85%
LGND
88.48
-3.46
-3.76%
LPTN
0.25
+0.02
+8.70%
MBVX
1.8
+0.05
+2.86%
MEIP
1.8
-0.02
-1.10%
MNOV
3.05
+0.1
+3.39%
MRTX
26.57
+0.75
+2.90%
MSTX
0.48
-0.01
-1.03%
NBIX
47.05
+0.67
+1.44%
NUVA
52.01
-0.71
-1.35%
ONCS
5.77
+0.39
+7.25%
ONVO
2.45
-0.28
-10.26%
OREX
2.68
-0.09
-3.25%
OTIC
21.45
-1.22
-5.38%
QDEL
20.28
-0.31
-1.51%
RCPT
231.96
0.00
0.00%
RGLS
8.26
-0.07
-0.84%
RMD
50.75
-1.19
-2.29%
SCIE
0.014
0.00
0.00%
SPHS
0.85
-0.05
-5.56%
SRNE
12.46
-0.22
-1.74%
TROV
5.72
-0.23
-3.87%
VICL
0.61
+0.02
+3.35%
VOLC
18
0.00
0.00%
ZGNX
18.48
-0.74
-3.85%
Home » Bio: Keith Murphy

Bio: Keith Murphy

Keith Murphy, chairman and chief executive officer, is a veteran of biotechnology startup Alkermes, Inc, where he played a central role on the development team for their first approved product, Nutropin (hGH) Depot. He moved to Amgen in 1997 and developed several other novel formulation and device products. He has more than 17 years of experience in biotechnology, including serving in product strategy and director of process development roles at Amgen. His 10 years at Amgen included four years as global operations leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. He holds a B.S. in chemical engineering from MIT and is an alumnus of the UCLA Anderson School of Management.